Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEACH: Donor-derived MSCs for Tolerance Induction in Kidney Transplant Recipients
NCT03504241Phase 1Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jul 2018
- Primary completion
- Sep 2023
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of donor-derived mesenchymal stromal cells in kidney transplantation (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Proportion of Participants Who Achieve Operational Tolerance. Started Jul 2018; status: completed.
02
Drugs
donor-derived mesenchymal stromal cells
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT03504241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03504241.